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The role of cholesterol in eukaryotic membrane
protein function has been attributed primarily to an
influence on membrane fluidity and curvature. We
present the 2.8 A˚ resolution crystal structure of
a thermally stabilized human b2-adrenergic receptor
bound to cholesterol and the partial inverse agonist
timolol. The receptors pack as monomers in an
antiparallel association with two distinct cholesterol
molecules bound per receptor, but not in the packing
interface, thereby indicating a structurally relevant
cholesterol-binding site between helices I, II, III,
and IV. Thermal stability analysis using isothermal
denaturation confirms that a cholesterol analog sig-
nificantly enhances the stability of the receptor. A
consensus motif is defined that predicts cholesterol
binding for 44% of human class A receptors, sug-
gesting that specific sterol binding is important to
the structure and stability of other G protein-coupled
receptors, and that this site may provide a target for
therapeutic discovery.
INTRODUCTION
The b2-adrenergic receptor (b2AR) is a well-characterized mem-
ber of the class A G protein-coupled receptors (GPCRs) and is
expressed in pulmonary and cardiac myocyte tissue (Milligan
et al., 1994; Takeda et al., 2002). The b2AR and its close relative
b1AR sense epinephrine and norepinephrine in bronchial vascu-
lature and cardiac muscle, respectively, and a positive inotropic
response is elicited with b1AR and bronchial dilation associated
with b2AR. One class of small molecules, known as beta
blockers, have been used clinically in the management of
cardiac arrhythmias, where they are thought to evoke their an-
tagonistic effect mainly through b1AR, but also bind effectively
to b2AR. The high-resolution crystal structure of the b2AR fused
to T4-lysozyme (b2AR-T4L) and the structure of b2AR in complex
with a specific Fab fragment have recently been determined in
the presence of the beta blocker and partial inverse agonist
carazolol (Cherezov et al., 2007; Rasmussen et al., 2007;StructureRosenbaum et al., 2007). Timolol, a member of the first genera-
tion of beta blockers, has found extensive use in the treatment of
glaucoma by reducing intraocular pressure, as well as in the
treatment of high blood pressure and heart disease. Timolol
has been characterized as a partial inverse agonist of the
b2AR, where its efficacy varies from 28% to 90% inhibition of
basal activity depending on the assay conditions. It also has
high water solubility, making it a useful ligand for structural stud-
ies (Chidiac et al., 1994; Zimmerman and Kaufman, 1977).
Cholesterol is an essential component regulating the structure
and function of eukaryotic membranes and is thought to act
primarily through the modulation of membrane fluidity and main-
tenance of sphingolipid rafts and membrane microdomains
(Simons and Ikonen, 2000). In addition, cholesterol plays a well-
established regulatory role in a number of membrane proteins,
either indirectly through its ability to modulate the physical prop-
ertiesof lipidmembranes, or directly throughspecific interactions
with select protein systems (Burger et al., 2000; Lee, 2004). It has
been postulated that cholesterol may also play an important role
inGPCR function andpharmacology,where certain receptors are
thought to partition into or out of cholesterol-rich caveolae (Puca-
dyil andChattopadhyay, 2006). In addition, direct protein-choles-
terol interactions have been demonstrated for the oxytocin,
galanin, and serotonin1A receptors (Gimpl et al., 1997; Pang
et al., 1999; Pucadyil and Chattopadhyay, 2004).
Herein, we report the 2.8 A˚ resolution crystal structure of an
engineered b2AR in complex with timolol and two molecules of
cholesterol. The b2ARwasmodified both for enhanced crystalliz-
ability by incorporation of T4-lysozyme between helices V and VI
(b2AR(E122W)-T4L), and for stability through the introduction of
a point mutation in the transmembrane domain (E1223.41W). Bal-
lesteros-Weinstein numbering is used throughout the text as su-
perscripts to the protein numbering (Ballesteros and Weinstein,
1995). Despite these modifications, the engineered receptor
retains nearly native ligand binding and signaling properties
(Rosenbaum et al., 2007; Roth et al., 2008).
In comparison to our previous b2AR-T4L structure, we reveal
unambiguous structural evidence of a specific cholesterol-bind-
ing site for amembrane protein. In contrast to the high-resolution
structure with carazolol (carb2AR-T4L), the cholesterol molecules
here are not involved in the crystal packing interface and do not
appear to be associated with the covalently attached palmitic
acid. We further demonstrate that the more water-soluble16, 897–905, June 2008 ª2008 Elsevier Ltd All rights reserved 897
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Cholesterol Binding to the b2-Adrenergic Receptorcholesterol analog cholesteryl hemisuccinate (CHS) has an effect
on thermal stability of the detergent-solubilized receptor in the
presence and absence of timolol, and that cholesterol incorpora-
tion into native insect cell membranes modifies the ligand-bind-
ing properties of the heterologously expressed receptor. We
also report the binding mode for the partial inverse agonist
timolol, which is bound at the orthosteric binding site of the
receptor (timb2AR(E122W)-T4L) and engages in many of the
same key interactions with the protein as carazolol, but with
some important differences.
RESULTS AND DISCUSSION
Crystal Generation and Structure Solution
High-level expression of b2AR(E122W)-T4L was performed in
Spodoptera frugiperda (Sf9) insect cells using standard proto-
cols (See Experimental Procedures). A simplified purification
scheme was enabled by the presence of the E122W mutation,
which resulted in a higher yield of functionally active receptor
in the folded state than for the wild-type (85% for E122W versus
25% for wild-type), as judged by size exclusion chromatography
using a fluorescent-labeled alprenolol probe and traditional
binding assays (Roth et al., 2008). This shift to a functionally
folded receptor eliminates the need for a ligand affinity chroma-
tography step in the purification. In addition, the high expression
levels of 2 mg of receptor per liter of cell culture enabled a single
metal-affinity chromatography step to achieve greater than
90% homogeneity, thus mitigating the effects of delipidation
on the final purified protein. We purified, crystallized, and deter-
mined the three-dimensional structure of b2AR(E122W)-T4L in
the presence of a saturating concentration of S-()-1-(t-butyla-
mino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxyl]-2-propanol
maleate (timolol) (Supplemental Data) Table 1. Comparison be-
tween timolol-bound b2AR(E122W)-T4L (
timb2AR(E122W)-T4L)
and carazolol-bound carb2AR-T4L (PDB ID: 2RH1) (overall root
mean squared deviation [rmsd]: 1.8 A˚, receptor rmsd: 0.34 A˚)
reveals a change in the relative tilt angle between T4L and the re-
ceptor, as well as a few minor shifts in intracellular loop 2 and
extracellular loop 3 that may be explained by the monomers
packing in a higher symmetry space group with different crystal
packing interactions (Figure 1A). In addition, the relative orienta-
tion between the two domains of T4L has shifted. However, as
indicated, the receptor portion of the fusion protein is very similar
between the two crystal structures. As such it is difficult to ex-
plain the occurrence of the altered space group as the conditions
used for crystallization of each species are very similar. Thus, it is
necessary to examine the differences in the protein and in its
preparation. There are three possibilities for the observed shift
in intermolecular interactions. The stabilizing mutant is altering
the packing environment either through loss of a buried charge
or through increased interactions with the monoolein lipid mem-
brane. This possibility is supported by the presence of electron
density for a lipid species adjacent to the W1223.41 modeled as
monoolein in the current structure. No corresponding density
was seen in this region for the carb2AR-T4L structure, despite
higher resolution data. A second related possibility is the pres-
ence of endogenous insect plasma membrane lipid being
retained through the shortened purification protocol. The final
possibility is that the shortened length of the C terminus in the898 Structure 16, 897–905, June 2008 ª2008 Elsevier Ltd All rightscurrent structure enables an altered crystal packing environment
despite the fact that the same number of residues are ordered
at the C terminus in both structures. Given the current informa-
tion, it is impossible to distinguish between these three possibil-
ities, although the first two seem more plausible given that the
majority of interreceptor packing interactions occur within the
lipid membrane.
Timolol Binding Interactions
Given the established similarity between b2AR and b2AR(E122W)
(Roth et al., 2008), as well as between b2AR and b2AR-T4L
(Rosenbaum et al., 2007), we feel confident in drawing relevant
conclusions from studies focusing on the molecular interactions
associated with b2AR and its small molecule effectors using the
b2AR(E122W)-T4L system, which we show here is structurally
equivalent to carb2AR-T4L. The binding orientation of timolol is
Table 1. Data Collection and Refinement Statistics
timb2AR(E122W)-T4L
Data collection (APS GM/CA CAT ID-B/D, 10 mm beam)
Space group P212121
a, b, c (A˚) 40.0, 75.7, 172.7
No. of reflections processed 54,405
No. unique reflections 12,782
Resolution (A˚)a 50-2.8 (3.0-2.8)
Rsym 14.3 (56.9)
Mean I/s(I) 6.9 (1.9)
Completeness (%) 94.0 (91.0)
Redundancy 4.2 (2.9)
Refinement
Resolution (A˚)a 20-2.8 (3.0-2.8)
No. reflections (test set) 12,782 (640)
Rwork/Rfree 23.1(30.2)/27.3(38.3)
No. atoms 3700
Protein 3528
Ions, lipids, ligand and other 152
Water 20
Overall B values (A˚2) 69
b2AR 63
T4-Lysozyme 80
Ligand 49
Cholesterol #1 71
Cholesterol #2 84
Lipid 71
Rmsds
Bond lengths (A˚) 0.010
Bond angles () 1.313
Ramachandran plot statistics (%):
Most favored regions 98.2
Additionally allowed regions 1.8
Disallowed regions 0
Rsym = Shkl jI(hkl) < I(hkl) > j / Shkl(hkl), where < I(hkl) > is the mean of the
symmetry equivalent reflections of I(hkl).
a Highest resolution shell is shown in parentheses.reserved
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Cholesterol Binding to the b2-Adrenergic Receptorsimilar to that of carazolol, where the oxypropanolamine tail
forms strong interactions with the polar triad (Asp1133.32,
Asn3127.39 and Trp3167.43), and the morpholino-thiadiazole
head group binds in a similar orientation to the carbazole head
group of carazolol (Figure 1B). However, two subtle yet relevant
differences occur between the carazolol and timolol binding
modes. The thiadiazole ring of timolol binds deeper into the re-
ceptor pocket allowing an additional hydrogen bonding interac-
tion with Thr1183.37. Second, an additional polar interaction is
formed between the ether moiety of the morpholino ring of timo-
lol and Asn2936.55, which has been implicated in agonist binding
and the transfer of conformational information to the G protein
coupling interface (Hannawacker et al., 2002; Wieland et al.,
1996). Due to hydrogen bonding between Asn2936.55 and
Tyr3087.35, both residues have slightly altered side-chain
rotamers relative to carb2AR-T4L to accommodate the recep-
tor-timolol interaction (Figure 1B). Although a direct comparison
of inverse agonism between timolol and carazolol has not been
reported, a study describing the suppression of basal activity
of b2AR by various ligands resulted in 28% suppression by timo-
lol and partial enhancement of signaling by carvedilol, a chemi-
cally homologous ligand to carazolol (Baker et al., 2003). Another
study of the suppression of basal activity of b2AR indicated
a much stronger inverse agonism effect of timolol (Chidiac
et al., 1994) and carazolol itself suppressed 50% basal activity
in a reconstituted liposome system (Rasmussen et al., 2007).
These data indicate that the magnitude of inverse agonism is
context dependent, although one would expect the rank order
of inverse agonist efficacy should remain constant.
The b2AR Cholesterol-Binding Site
Over the past few years, studies highlighting the effect of choles-
terol depletion on ligand-binding characteristics of a few recep-
tors in membranes have been reported and recently reviewed
(Pucadyil and Chattopadhyay, 2006). In addition, the thermal
stability of both the oxytocin receptor and the b2AR is improved
in the presence of cholesterol and CHS, respectively (Gimpl and
Fahrenholz, 2002; Yao and Kobilka, 2005). For the oxytocin re-
ceptor, cholesterol or cholesterol analogs that enhance thermal
stability also shift the receptor to the high-affinity agonist binding
state, implying allosteric modulation by cholesterol.
The structure of carb2AR-T4L had interpretable density for
three molecules of cholesterol per monomer of protein with
visible density for the palmitate moiety that is posttranslationally
attached to Cys341 and located between cholesterol molecules
2 and 3 of a symmetry-related monomer (Figure 2A). Due to the
position of the cholesterol molecules relative to the crystal-pack-
ing interface, the biological relevance of the binding sites could
not be decoupled from potential crystal-packing artifacts
(Figure 2A), and the orientation of the sterol ring relative to the re-
ceptor could not be established. With the generation of crystals
for timb2AR(E122W)-T4L in a higher symmetry space group and
the antiparallel orientation of the receptor molecules within the
asymmetric unit, the role of cholesterol in crystal packing is
reduced (Figure 2B). The retention of binding sites for cholesterol
1 and 2 in the current structure indicate that two sites are not
experimental artifacts and that cholesterol binding in this region
may be physiologically relevant. The electron density for choles-
terol 1 in the timb2AR(E122W)-T4L does not support the position
seen in the carb2AR-T4L structure—rather, a 90
 rotation and
slight translation along the long axis of the molecule are neces-
sary for optimal fitting of the experimental electron density (Fig-
ures 2C and 2D). This alternate orientation results in the choles-
terol molecules packing with the sterol ring system of cholesterol
2 related to cholesterol 1 by an approximately 2-fold rotation and
a slight translational shift along an axis parallel to the ring system.
Both cholesterol molecules bind in a shallow surface groove
formed by segments of helices I, II, III, and IV and thus provide
an increase in the intramolecular occluded surface area, a pa-
rameter linked to the enhanced stability of proteins from thermo-
philic organisms and used to compare the internal packing of he-
lices in membrane proteins relative to soluble protein (DeDecker
et al., 1996; Eilers et al., 2000, 2002). We use the occluded
surface area method to analyze packing value (PV) differences
Figure 1. Overview of the timb2AR(E122W)-
T4L Structure
(A) The location of the tryptophan mutation is indi-
cated, as well as the position of the ligand timolol.
Two cholesterol molecules (orange) occupy
roughly the same position as in the carb2AR-T4L
structure. Two lipid monoolein molecules (yellow)
are located in the proximity of the E1223.41W
mutation in a crystal-packing interface and one
by helix I. The tilt angle between the receptor
and T4L is markedly different between the
timb2AR(E122W)-T4L structure (green ribbon trace)
and carb2AR-T4L (blue ribbon trace). This intramo-
lecular conformational change is likely due to an
altered crystal-packing environment.
(B) Timolol and carazolol are both shown and
colored magenta and green, respectively. Intrare-
ceptor polar interactions are represented by black
dashed lines; receptor-ligand polar interactions
are represented by red dashed lines. In addition to the interactions betweenAsp1133.32, Asn3127.39, and Tyr3167.43 and the oxypropanolamine tail of both ligands,
the morpholino oxygen of timolol is within hydrogen-bonding distance of Asn2936.55, which has an altered side-chain rotamer relative to the carazolol-bound
structure (orange side chains). Thus, the head group of timolol participates in a second hydrogen bonding network between Tyr3087.35, Asn2936.55 and
Ser2045.43. In addition, the thiadiazole ring protrudes deeper into the binding pocket than the analogous ring of carazolol, allowing a stronger interaction between
the thiadiazole group and Thr1183.37.Structure 16, 897–905, June 2008 ª2008 Elsevier Ltd All rights reserved 899
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Cholesterol Binding to the b2-Adrenergic ReceptorFigure 2. Structural Evidence for Cholesterol Specificity in Binding
(A) Crystal-packing environment of the previously published (Cherezov et al., 2007; Rosenbaum et al., 2007) carb2AR-T4L (PDB ID: 2RH1) where the receptor
monomers pack in a parallel orientation. Three cholesterol molecules are bound to each monomer and a palmitic acid alkyl chain from the crystallographically
related monomer that is located between cholesterol 2 and 3. The four lipid molecules form an eight-membered lipid sheet when the crystallographically related
monomer is generated (top and bottom figures).
(B) Crystal-packing environment of timb2AR(E122W)-T4L structure where the receptor monomers pack in an antiparallel orientation. Cholesterol 1 and 2 are
retained in the new crystal form and are not implicated in packing interactions (top and bottom figures).
(C) Experimental electron density for the cholesterol molecules is shown in stereo. The FoFcmaps contoured at 2swere calculated after omitting the cholesterol
contribution to the overall phases and randomly shaking the model to reduce phase bias.
(D) Comparison of cholesterol binding between timb2AR(E122W)-T4L (yellow) and
carb2AR-T4L (cyan). Cholesterol 2 binds in approximately the same orientation
between the two structures. Cholesterol 1 is modeled differently in the current structure with a 90 rotation and a 1.9 A˚ translation about the long axis of the mol-
ecule. These modifications were necessary to optimally fit the experimental electron density.between the transmembrane helices compared to each other
and to their equivalent helices in rhodopsin (PDB ID: 1U19)
(Pattabiraman et al., 1995). It is interesting to note that overall,
the rhodopsin helical bundle has slightly tighter packing interac-
tions than b2AR (PV: 0.43 versus 0.42), perhaps reflective of its
greater stability. In the absence of cholesterol, helix IV has the
loosest packing of all the transmembrane helices in b2AR (PV
without cholesterol: 0.37), whereas it is tightly packed in rhodop-
sin (PV: 0.45). Binding interactionswith cholesterol 1 increase the
packing for this helix (PV with cholesterol: 0.39), which is
indicative of a decrease in mobility (Figures 3A and 3B). Both
cholesterol molecules contribute equally to the increase in
packing of helix II upon cholesterol binding (Figures 3A and
3B). However, in the absence of cholesterol, helix II has the
second highest occluded surface area of the transmembrane
helices so that the marginal gain from cholesterol interactions900 Structure 16, 897–905, June 2008 ª2008 Elsevier Ltd All rightson this helix would not significantly affect the mobility of the helix
or the overall thermal stability of the protein. We show that
cholesterol increases the packing interactions for both helix II
and IV explaining structurally the observed increase in thermal
stability; however, helix IV is still unable to achieve the high
degree of intramolecular packing interactions associated with
rhodopsin, indicating that this helix is perhaps one of theweakest
points in the b2AR fold. While the overall effect on normalized
occluded surface area upon cholesterol binding appears small,
the differences between rhodopsin and b2AR over the 7-trans-
membrane bundle are also very small, even though the resulting
change in thermostability appears quite significant. Similarly,
comparison of hyperthermophilic proteins to their mesophilic
counterparts indicates an increase in normalized occluded sur-
face area of 4% at the most, putting the change in packing and
its relationship to stability on a more absolute scale (Eilersreserved
Structure
Cholesterol Binding to the b2-Adrenergic ReceptorFigure 3. Analysis of Helical Packing and Thermal Stability Increase Due to Cholesterol Binding
(A) The receptor is colored by normalized occluded surface area. Red thick lines indicate the compact areas of the receptor and blue thin lines are the least com-
pact. Helix IV has the lowest packing of the seven helices in the tertiary structure, particularly on the cytoplasmic end. Cholesterol binding stabilizes the receptor
by increasing packing constraints, especially in the vicinity of the cytoplasmic end of helix IV. The values range from 10% to 70%of the total available surface area
being involved in packing interactions.
(B) Differences in the normalized occluded surface area of the receptor due to cholesterol binding. Values range from 0% to 15% increase in packing of available
surface area due to cholesterol binding, with the most significant increases seen for residues on helices II and IV.
(C) Molecular surface representation of the receptor and cholesterol. The green-colored surface corresponds to atoms on both cholesterol and the receptor that
are within 4 A˚ of each other. The blue-colored surface corresponds to atoms on the receptor that are 4 and 5 A˚ from the cholesterol molecules. In the second
panel, the cholesterol molecules have been lifted out of the binding groove to better show the interactions and the binding groove.
(D) Isothermal CPM determination of the half-life of denaturation in the presence of 1 M GnHCl with and without both CHS and timolol. The thickness of the line
represents the 95% confidence interval over three replicates, and the fitted half lives are indicated next to the respective curves. Both timolol and cholesterol
cause an approximate 5-fold increase in half-life under these conditions. In combination, the effect is almost 16-fold relative to apo.et al., 2002). It is likely that the main effect of cholesterol on sta-
bility is mediated through its effect on helix IV, where cholesterol
1 serves as a bridge to helix II, which forms many intramolecular
interactions contributing to the core of the receptor fold (Figures
3B and 3C).
We have further characterized the thermal stability of
b2AR(E122W)-T4L solubilized in the detergent dodecylmaltoside
(DDM) in the presence and absence of CHS and timolol by mon-
itoring the extent of covalent coupling of receptor cysteines to
the thiol-reactive dye, 7-diethylamino-3-(40-maleimidylphenyl)-
4-methylcoumarin (CPM), as a function of time in the presence
of 1 M guanidinium hydrochloride (GnHCl) (Figure 3D; Alexan-
drov et al., 2008). The half-life of thermal denaturation of
b2AR(E122W)-T4L at 35
Cchanges significantly upon incorpora-Structuretion of both timolol and CHS (Figure 3D). The overall stabilizing
effect of CHS in 1 M GnHCl results in a 5-fold increase in the
half-life of protein denaturation in the absence of timolol and
a 2-fold increase over protein bound to timolol alone. Relative
to the apo protein, with a half-life of 8 min, incorporation of
both ligands simultaneously increases the half-life to 127 min,
which is almost a 16-fold improvement in stability (Figure 3D).
The specific interaction of other membrane proteins with
cholesterol has previously been postulated and a consensus
sequence for cholesterol binding has been proposed within the
context of the peripheral-type benzodiazepine receptor (Li and
Papadopoulos, 1998). Cholesterol binding appears to be depen-
dent on the presence of an incipient cleft located at a membrane
interfacial region, which contains at least one aromatic residue16, 897–905, June 2008 ª2008 Elsevier Ltd All rights reserved 901
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Cholesterol Binding to the b2-Adrenergic Receptorand a positively charged residue capable of participating in elec-
trostatic interactions with apical hydroxyl group (Epand et al.,
2006; Jamin et al., 2005). The cleft formed by b2AR helices I, II,
III, and IV is capable of accommodating two cholesterol mole-
cules although there are a reduced number of interactions
between b2AR and cholesterol 2. Interactions with helix IV are
perhaps most analogous to the previously defined cholesterol
binding motif and together with an additional site on helix II
form a receptor cholesterol consensus motif (CCM) defined by
four spatially distributed interactions with cholesterol 1. The aro-
matic Trp1584.50 is almost universally conserved (94%) among
class A GPCRs and appears to contribute the most significant
interaction with the sterol ring of cholesterol 1 through a CH-p
interaction and the edge of ring D. The hydrophobic Ile1544.46
interacts with rings A and B and is 60% homology conserved
(35% by identity). An aromatic residue from helix II, Tyr702.41
in b2AR, forms Van der Waals interactions with ring A of choles-
terol 1 and hydrogen bonds to Arg1514.43. Importantly, a positive
charge at an analogous position to Arg1514.43 is only 22% con-
served with either arginine or lysine occupying the position.
However, due to the nonspecific nature of electrostatic interac-
tions in the interfacial region of the membrane, nearby positions
with positive charge may also serve the role of interacting with
the cholesterol hydroxyl group, the limits of which will need
to be established structurally. Consideration of the spatial distri-
bution of conserved residues that are important for cholesterol
binding in b2AR allow the definition of a strict-CCM for choles-
terol interaction within the class A receptors based on the
Ballesteros-Weinstein numbering scheme as follows: [4.39-
4.43(R,K)]—[4.50(W,Y)]—[4.46(I,V,L)]—[2.41(F,Y)] where 21% of
human class A receptors (Table 2) are predicted to bind choles-
terol at the same site as b2AR (Figure 4A). The four positions
within the strict-CCM are listed according to their perceived
rank order of binding interactions, with the positively charged
position contributing the most binding energy and the aromatic
residue on helix II contributing the least.
The effect of cholesterol binding on the properties of any
receptor will likely vary across the class and will need to be
determined for each member. For instance, both the oxytocin
and serotonin1A receptors contain the strict-CCM sequence
and are affected by cholesterol. In both receptors, cholesterol in-
corporation led to a dramatic increase in agonist affinity, and for
oxytocin an increase in thermal stability was detected (Gimpl
et al., 1997; Gimpl and Fahrenholz, 2002; Pucadyil and Chatto-
padhyay, 2004). On the other hand, cholesterol stabilizes rho-
dopsin in the inactive state through indirect effects on the plasma
membrane curvature and molecular simulation argues for a non-
specific binding of cholesterol (Grossfield et al., 2006; Niu et al.,
2002). In b2AR, addition of cholesterol induces an increase in the
affinity for the partial inverse agonist timolol, but no change is ob-
served for the full agonist isoproterenol (Figure 4B). Furthermore,
the stability enhancement observed upon CHS incorporation in
no way precludes the production of a sufficiently stable and
active receptor in Spodoptera frugiperdawhich have significantly
less cholesterol than mammalian cells (Marheineke et al., 1998).
While the physiological effect of cholesterol binding to b2AR is
unknown, it has been established that b2AR preferentially se-
questers to cholesterol-rich caveolae in neonatal rat cardiomyo-
cyte cultures (Ostrom et al., 2001; Rybin et al., 2000; Steinberg,902 Structure 16, 897–905, June 2008 ª2008 Elsevier Ltd All rights r2004), and partitions out of the caveolae upon stimulation (Rybin
et al., 2000). While this compartmentalization has been shown to
bedue in part to the presenceof aC-terminal PDZbinding domain
that directs the trafficking of b2AR to caveolae (Xiang and Kobilka,
2003), receptor cholesterol interactionsmay also play a role in de-
fining the traffickingproperties ofb2ARandotherGPCRs. Further-
more, sequence disparities in the cholesterol-binding site among
receptorsmay potentiate the trafficking effect of cholesterol bind-
ing, analogous to the trafficking and cholesterol sequestration ef-
fects observed for caveolin and other cholesterol-bindingproteins
(Epand et al., 2005).
The presence of an aromatic residue at postion 2.41 is the
most restrictive of the four rules and also appears to be the least
important for binding of cholesterol based on the structure. In the
absence of this requirement, 44% of human class A receptors
would contain the less restrictive CCM and should still bind cho-
lesterol in a similar manner as b2AR (Figure 5, Table 2). Although
future mutagenesis studies will reveal the actual rank order
importance of these positions in cholesterol binding, it is increas-
ingly apparent that sterols play an important direct role GPCR
stability and pharmacology.
EXPERIMENTAL PROCEDURES
See the Supplemental Data for additional experimental procedures.
Table 2. List of Receptors with the CCM Motifs
Strict-CCM CCM
HTR1A DRD3 HTR5A LGR7
HTR1B DRD1 ADRA2A MTNR1A
HTR1E EDG1 ADRA2B MTNR1B
HTR1F EDG2 ADRA2C GPR50
HTR2A EDG3 ADORA1 MC1R
HTR2B GPR10 ADRB1 MTLR1
HTR2C GPR19 ADRB3 NPFF1
HTR4 GPR21 CNR2 NPGPR
HTR6 GPR52 CCKAR TACR3L
HTR7 MC3R DRD4 NTSR2
ADRA1A MC4R DRD5 NPY1R
ADRA1B MC5R EDNRB OR10H1
ADRA1D TACR1 FPR1 OR10H2
ADORA2A TACR2 GALR1 OR10H3
ADORA3 TACR3 GALR2 OR10J1
CHRM1 NTSR1 GALR3 OR11A1
CHRM2 NPY2R CCKBR OPN4
CHRM3 OPN1SW GHSR LTB4R
CHRM4 OPN1MW GPR45 PTGER3
CHRM5 OPN1LW GPR63 PTGER4
MC2R HCRTR1 GPR72 PTGFR
ADRB2 HCRTR2 GPR1 TBXA2R
DRD2 OXTR GPR3 TRHR
GNRHR AVPR1A
HRH1
HRH2eserved
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Cholesterol Binding to the b2-Adrenergic ReceptorFigure 4. Structurally Determined Receptor Cholesterol Consensus Motif and the Effects of Cholesterol Association on Ligand-Binding
Properties of b2AR
(A) The sites of importance in the receptor cholesterol consensus motif are displayed with the b2AR side-chain positions. Site 1 (blue) at the cytoplasmic base of
helix IV spanning positions 4.39-4.43 fulfills the CCM requirement if one or more of these positions contains an arginine or lysine residue. Site 2 (cyan) at position
4.50 on helix IV contributes CH-p hydrogen-bonding interactions (represented as space-filling atoms) and is the most conserved site with tryptophan occupying
the position in 94% of class A receptors. Site 3 (green) at position 4.46 on helix IV contributes van der Waals interactions (represented as space-filling atoms) to
cholesterol binding and fulfills the CCM requirement if isoleucine, valine, or leucine occupy the position. Site 4 (orange) on helix II at position 2.41 can be either
phenylalanine or tyrosine to define the strict-CCM requirement.
(B) Competition binding curves for b2AR(E122W)-T4L in the presence and absence of cholesterol. Cholesterol in complex with b-methyl cyclodextran
was added to the expression cultures 24 hr after expression. A 2-fold reduction in the Ki for timolol is observed due to cholesterol addition, but not for
isoproterenol.Expression and Purification
b2AR(E122W)-T4L was identical to b2AR-T4L in all but two features: (1) residue
122 was mutated from a glutamate to a tryptophan using standard site-di-
rected mutagenesis protocols, and (2) the C terminus was further truncated
to residue 348 eliminating a total of 65 residues. High-titer recombinant
baculovirus was obtained using standard protocols in the Bac-to-Bac system
(Invitrogen) and used to infectSpodoptera frugiperda (Sf9) insect cells at amul-
tiplicity of infection of five and the expression was allowed to proceed for 48 hr.
Insect cell membranes were initially disrupted by nitrogen cavitation in a hypo-
tonic buffer containing 10 mMHEPES (pH 7.5), 20 mMKCl, and 10mMMgCl2.
Extensive washing of the membranes was performed by repeated centrifuga-
tion and dounce homogenization to strip the membranes of soluble and mem-
brane associated proteins. Membraneswere flash-frozen and stored at80C
until further use. Prior to solubilization, prepared membranes were thawed on
ice in the presence of 1 mM timolol, 2 mg/ml iodoacetamide, and protease in-
hibitors. Membranes were then solubilized by incubation in the presence of
0.5%w/v DDM for 2-4 hr at 4C. After solubilization, the solution was clarified
at 100,0003 g and the resulting supernatant was incubatedwith Co2+ charged
TALON IMAC resin overnight at 4C. The resin was washed with 20 mM imid-
azole to remove impurities, followed by an elution of the receptor with 200 mM
imidazole. An additional IMAC step after desalting was used to concentrate
and deglycosylate (PNGaseF) the receptor (increasing purity up to 98%).
The protein was maintained in 20 mM HEPES (pH 7.5), 150 mM NaCl,
0.05%DDM, 0.01%CHS, and 1 mM timolol throughout the purification unless
otherwise indicated. Timolol concentration was increased to 5 mM on the sec-
ond IMAC column to avoid ligand depletion in the subsequent concentration
step, which incorporated a 600 ml Vivaspin cartridge with a 100 kDa molecular
weight cutoff.StructureCrystallization and Structure Determination
Crystals were generated from a 10% w/w cholesterol/monoolein lipidic cubic
phase after reconstituting the protein from a 30 mg/ml solution and overlaying
the lipid phase with a solution of 28% w/v PEG 400, 300 mM K Formate,
100 mM Bis-tris propane (pH 7.0), and 2 mM timolol. Crystals were obtained
from 25 nl of cubic phase and harvested directly from glass sandwich plates
in which they were grown (Cherezov et al., 2004). Diffraction data were col-
lected from ten microcrystals and merged to obtain a 94% complete 2.8 A˚
dataset. Phases were obtained by molecular replacement and the refined
atomic positions were submitted to the Protein Data Bank (PDB ID: 3D4S)
(See Supplemental Data for additional details).
Thermal Stability Assay
Thermal stability data were collected using a modified procedure incorporat-
ing a thiol-reactive coumarin maleimide, 7-diethylamino-3-(40-maleimidyl-
phenyl)-4-methylcoumarin (CPM) (Alexandrov et al., 2008). The data were col-
lected at 35C in the presence of GnHCL at three different concentrations. The
chemical denaturant was included to speed the process of unfolding, thereby
minimizing the effects of dehydration on data processing errors. Protein was
purified according to standard procedures until the final Ni-NTA purification
and concentration step, at which point timolol and CHS were washed from
the protein with five column volumes of buffer. The protein was then eluted
at approximately 2 mg/ml as a 103 stock. The protein was then diluted 3-
fold into a 50 mM HEPES (pH 7.5), 150 mM NaCl buffer containing 2 mg of
CPM dye (diluted from a 4 mg/ml stock in dimethyl formamide) and incubated
at 4C for 10 min. Various combinations of timolol and CHS in DDM were then
added to the mixture at 23 final concentration and allowed to equilibrate for
30 min at 4C before the final dilution to working volume with the appropriate16, 897–905, June 2008 ª2008 Elsevier Ltd All rights reserved 903
Structure
Cholesterol Binding to the b2-Adrenergic Receptorconcentration of GnHCl in the assay buffer. Data was collected as soon as
possible after the addition of the chemical denaturant to reduce the degree
of unfolding prior to measurement. Fluorescence of the CPM dye was
measured on a Tecan Genios Pro fluorescent plate reader using 340 nM exci-
tation filter with a 35 nM bandpass and a 475 nM emission filter with a 20 nM
bandpass. Readings were measured every minute for 3 hours. The data were
fit to a single exponential decay curve using GraphPad Prism Software (San
Diego, CA).
ACCESSION NUMBERS
Coordinates and structure factors have been deposited in the Protein Data
Bank with identification code 3D4S.
SUPPLEMENTAL DATA
Supplemental Data include one figure, Supplemental Experimental Proce-
dures, and Supplemental References and are available with this article online
at http://www.structure.org/cgi/content/full/16/6/897/DC1/.
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Figure 5. Venn Diagram Illustrating the Abundance of Specific
Elements of the CCM Among Human Class A GPCRs
The individual circles are proportional to the percentage of receptors possess-
ing each element. Twenty-one percent of human class A receptors contain the
entire four-component strict-CCM. If the requirement for an aromatic at posi-
tion 2.41 is removed, 44% of human class A receptors would contain the less
restrictive CCM motif. The removal of this position from the strict-CCM is jus-
tified by the relatively long van der Waals interactions between cholesterol and
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